Purple Biotech Ltd.
(NASDAQ: PPBT)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $0.36 | Change: -0.01 | %Change: -1.95% | Volume: 104,573 |
Open: | $ 0.37 | Volume: | 104,573 | |
---|---|---|---|---|
High: | $ 0.37 | Yield(%) | 0.00 | |
Low: | $ 0.36 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 10.24M | |
EPS ($) | -0.82 | Shares Out: | 27.66M |
% Price Change (last 4 weeks): | -40.36 |
---|---|
% Price Change (last 13 weeks): | -45.18 |
% Price Change (last 26 weeks): | -52.01 |
% Price Change (last 52 weeks): | -73.40 |
% Price Change (year to date): | -52.56 |
Return on Equity (%): | -49.02 |
---|---|
Return on Assets (%): | -40.19 |
Return on Invested Capital (%): | -45.85 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $0.56 |
---|---|
200-day Moving Average: | $0.81 |
Avg. Daily Vol. (last 50 days): | 370,709 |
Avg. Daily Vol. (last 200 days): | 171,382 |
52-wk high: | $1.80 |
52-wk low: | $0.30 |
Bid: | $0.34 |
Ask: | $0.40 |
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
|
Purple Biotech Ltd.
Science Park 4 Oppenheimer Street Rehovot TA 7670104 Phone: 972.3.933.3121 Fax: n/a http://ww.purple-biotech.com |
Earnings (1year) ($): | -0.82 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 1.39 |
Cash Flow ($): | -0.80 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 0.56 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 2.20 |
---|---|
Current Ratio (x): | 2.20 |
LT Debt/Equity (x): | 0.48 |
Total Debt/Equity (x): | 1.03 |